The North America Transcriptomics Market is expected to witness market growth of 6.9% CAGR during the forecast period (2021 2027).
Technological improvements and a surge in research grants from various institutes are two reasons that are expected to propel the transcriptomics market during the forecasting period. Moreover, the potential for RNAs to be used as diagnostic biomarkers and predictors of treatment response is the key industry trend. Previously, transcriptomics applications were limited to basic gene expression profiling and other research applications like determining the amount of RNA in a biological sample and studying gene expression. Other more prominent transcriptome uses are reported only after the simplification of transcriptomics technologies, reduction in technological costs, and increased awareness of transcriptomics technologies among both scientific intelligentsia and the general public.
The rapid development of structure-based medication designs, increased focus on transcriptomics research, and significant investment in biopharmaceutical research and development are the key trends of the regional market. In addition, rising funding in pharmaceutical research and development by the governments of different regional countries is expected to create a conducive environment for the regional market players. North America, particularly the United States, is home to the majority of key players of transcriptomic systems, platforms, equipment, and technologies. Rebus Biosystems, for example, debuted its spatial transcriptomics analysis platform 'spatial omics' system in 2021, which is aimed to allow researchers to examine the output of individual cells across tissue samples in more detail.
North American countries have experienced and continue to incur a major economic and healthcare burden as a result of COVID-19's high transmission rate and lack of therapy. The sale of reagents and consumables used in transcriptomics analysis has decreased as a result of the closure of research and academic institutes.
The US market dominated the North America Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $2,674 million by 2027. The Canada market is poised to grow at a CAGR of 9.4% during (2021 - 2027). Additionally, The Mexico market is expected to exhibit a CAGR of 8.4% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
Technological improvements and a surge in research grants from various institutes are two reasons that are expected to propel the transcriptomics market during the forecasting period. Moreover, the potential for RNAs to be used as diagnostic biomarkers and predictors of treatment response is the key industry trend. Previously, transcriptomics applications were limited to basic gene expression profiling and other research applications like determining the amount of RNA in a biological sample and studying gene expression. Other more prominent transcriptome uses are reported only after the simplification of transcriptomics technologies, reduction in technological costs, and increased awareness of transcriptomics technologies among both scientific intelligentsia and the general public.
The rapid development of structure-based medication designs, increased focus on transcriptomics research, and significant investment in biopharmaceutical research and development are the key trends of the regional market. In addition, rising funding in pharmaceutical research and development by the governments of different regional countries is expected to create a conducive environment for the regional market players. North America, particularly the United States, is home to the majority of key players of transcriptomic systems, platforms, equipment, and technologies. Rebus Biosystems, for example, debuted its spatial transcriptomics analysis platform 'spatial omics' system in 2021, which is aimed to allow researchers to examine the output of individual cells across tissue samples in more detail.
North American countries have experienced and continue to incur a major economic and healthcare burden as a result of COVID-19's high transmission rate and lack of therapy. The sale of reagents and consumables used in transcriptomics analysis has decreased as a result of the closure of research and academic institutes.
The US market dominated the North America Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $2,674 million by 2027. The Canada market is poised to grow at a CAGR of 9.4% during (2021 - 2027). Additionally, The Mexico market is expected to exhibit a CAGR of 8.4% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- q PCR
- Microarrays
- Sequencing Technology
By Application
- Drug Discovery
- Diagnostics & Disease Profiling
- Others
By Component
- Consumables
- Instruments
- Software
- Services
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Transcriptomics Market by Technology
Chapter 5. North America Transcriptomics Market by Application
Chapter 6. North America Transcriptomics Market by Component
Chapter 7. North America Transcriptomics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Methodology
LOADING...
